
Xellar Secures $50 Million to Scale Human-Relevant Bio Intelligence
Moving beyond the limitations of animal testing, Boston-based Xellar Biosystems has closed $50 million in Series A and A+ funding to build a predictive biological infrastructure. The company plans to integrate organ-on-chip systems with AI-driven modeling to solve the industry-wide bottleneck of insufficient high-quality human biological data.

























